Future studies should therefore extend this bead-based approach by incorporating analyses of tumor-specific mutations or methylation patterns within HCC-related genes in cfDNA, or by evaluating additional protein markers (e.g., GPC3) in CTCs alongside AFP. This evidence concerns the gene GPC3 and hepatocellular carcinoma.